FOLD Stock Overview
A biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for FOLD from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Amicus Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.59 |
52 Week High | US$14.03 |
52 Week Low | US$8.79 |
Beta | 0.61 |
1 Month Change | 1.91% |
3 Month Change | -16.02% |
1 Year Change | -22.85% |
3 Year Change | 6.32% |
5 Year Change | -8.80% |
Change since IPO | -33.54% |
Recent News & Updates
Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Dec 30Amicus Therapeutics: Cheap Heading Into 2025
Dec 27Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden
Nov 10Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Oct 18Recent updates
Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Dec 30Amicus Therapeutics: Cheap Heading Into 2025
Dec 27Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden
Nov 10Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Oct 18'Boring' Amicus Therapeutics Is Making Progress
Sep 29Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Jul 02Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Aug 10Amicus Therapeutics Q2 2022 Earnings Preview
Aug 03Shareholder Returns
FOLD | US Biotechs | US Market | |
---|---|---|---|
7D | 0.5% | 2.1% | -0.2% |
1Y | -22.8% | -3.6% | 23.7% |
Return vs Industry: FOLD underperformed the US Biotechs industry which returned -3.6% over the past year.
Return vs Market: FOLD underperformed the US Market which returned 23.7% over the past year.
Price Volatility
FOLD volatility | |
---|---|
FOLD Average Weekly Movement | 4.6% |
Biotechs Industry Average Movement | 11.3% |
Market Average Movement | 6.5% |
10% most volatile stocks in US Market | 18.8% |
10% least volatile stocks in US Market | 3.3% |
Stable Share Price: FOLD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FOLD's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 517 | Brad Campbell | amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. Fundamentals Summary
FOLD fundamental statistics | |
---|---|
Market cap | US$2.89b |
Earnings (TTM) | -US$104.69m |
Revenue (TTM) | US$493.67m |
5.8x
P/S Ratio-27.4x
P/E RatioIs FOLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FOLD income statement (TTM) | |
---|---|
Revenue | US$493.67m |
Cost of Revenue | US$49.43m |
Gross Profit | US$444.24m |
Other Expenses | US$548.93m |
Earnings | -US$104.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.35 |
Gross Margin | 89.99% |
Net Profit Margin | -21.21% |
Debt/Equity Ratio | 217.8% |
How did FOLD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/29 23:56 |
End of Day Share Price | 2025/01/29 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amicus Therapeutics, Inc. is covered by 28 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
John Eade | Argus Research Company |
Michael Ulz | Baird |
Yun Zhong | Berenberg |